Patient Access to Affordable Medicines: How a Renegotiated NAFTA Could Keep Drug Prices High | Association for Accessible Medicines

Patient Access to Affordable Medicines: How a Renegotiated NAFTA Could Keep Drug Prices High

September 14, 2018

Friday, September 14, 2018
Noon–1:00 p.m.

1310 Longworth House Office Building
Committee on House Administration Hearing Room

On August 31, President Trump notified Congress of his intent to sign a trade agreement with Mexico. This agreement could have a significant impact on the United States’ economy, including prescription drug pricing and the emerging biosimilars market.

Please join the Association for Accessible Medicines (AAM) for a briefing to discuss the proposed NAFTA agreement, its impact on rising prescription drug prices and recommendations for a stronger agreement.

Panelists include:

Jeff Francer (Moderator)
Senior Vice President and General Counsel, Association for Accessible Medicines

Marcie McClintic Coates
Head of Global Policy, Mylan

David Mitchell
President and Founder, Patients for Affordable Drugs

Leigh Purvis
Director, Health Services Research, AARP

This briefing has been designed to comply with House and Senate ethics rules. Lunch will be provided.

To RSVP, contact Lindsey Novak

 

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.